HONG KONG, July 24, 2023– Lucence, a precision health company, announced today a strategic collaboration with Innovent Biologics, Inc. to improve access of Hong Kong patients with advanced bile duct cancer (cholangiocarcinoma) to the FDA-approved targeted treatment Pemazyre® (pemigatinib).
Under the agreement, Innovent will sponsor Lucence’s LiquidMARK™ Bile Duct test for Hong Kong patients with a diagnosis of bile duct cancer who fulfil criteria. LiquidMARK™ Bile Duct, powered by AmpliMARKTM next generation sequencing technology, is an ultrasensitive next-generation sequencing blood test that identifies relevant gene mutations – including the fibroblast growth factor receptor 2 (FGFR2) fusion gene that Innovent’s Pemazyre® is effective against. Patients with FGFR2 fusion identified through the LiquidMARK™ Bile Duct test will be eligible to receive Pemazyre® as second-line treatment.
Cholangiocarcinoma is often diagnosed at late-stage with very limited treatment options. This collaboration will improve access to accurate identification of FGFR2 fusions through an accurate and quick blood test – allowing more patients to benefit from effective targeted treatment.
Lucence contact:
- [email protected]
- Alex Wong
- +852 9742 6140